MedTrace Logo

A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults

NCT06601192 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2025-07-28

No results posted yet for this study

Summary

The purpose of the study is to assess the effect of a therapeutic and supratherapeutic dose of zelicapavir on the corrected cardiac QT interval relative to a placebo and positive control in healthy participants.

Conditions

  • RSV Infection
  • QTc Interval

Interventions

DRUG

zelicapavir (therapeutic dose)

Subjects will receive zelicapavir (TD) once per treatment period.

DRUG

zelicapavir (supratherapeutic dose)

Subjects will receive zelicapavir (SD) once per treatment period.

DRUG

Placebo

Subjects will receive zelicapavir matching placebo once per treatment period.

DRUG

moxifloxacin

Subjects will receive moxifloxin once per treatment period.

Sponsors & Collaborators

  • Enanta Pharmaceuticals, Inc

    lead INDUSTRY

Principal Investigators

  • Enanta Pharmaceuticals, Inc · Enanta Pharmaceuticals, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-15
Primary Completion
2025-02-02
Completion
2025-02-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06601192 on ClinicalTrials.gov